ribosomal protein S4X pseudogene 20Genealiases: RPS4P20 · RPS4X_9_1648
Q-omics provides the consensus-scored RPS4XP20 profile across patient tissues and cancer cell-line models. RPS4XP20 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RPS4XP20 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, RPS4XP20 RNA expression shows 7,201 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight CESC, COAD, and DLBC as cancer lineages where RPS4XP20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS4XP20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS4XP20 survival associations across molecular data types. RPS4XP20 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS4XP20 RNA expression–survival associations across cancer types. High RPS4XP20 expression shows unfavorable associations in SKCM and LUAD, but favorable associations in CESC, READ, BLCA and LUSC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for RPS4XP20 RNA expression.
This table summarizes RPS4XP20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPS4XP20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS4XP20 shows lower tumor expression in BLCA and higher tumor expression in COAD, READ, KIRP, KIRC and THCA. The COAD box plot shows higher RPS4XP20 RNA expression in tumor versus normal tissue (log2 FC = +0.376, t-test p < 0.001).
This table shows molecular features associated with RPS4XP20 in patient tissues and cancer cell lines. In patient samples, RPS4XP20 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
